Eledon Pharmaceuticals (ELDN) Other Non-Current Assets (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Other Non-Current Assets of $32.4 million for Q1 2026, up 9048.59% year-on-year from $354000.0 in Q1 2025, and up 9957.76% on a QoQ basis from $322000.0 in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Other Non-Current Assets data on file, last reported at $32.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 9048.59% year-over-year to $32.4 million; the trailing twelve-month figure through Mar 2026 stood at $32.4 million (up 9048.59% YoY), and the FY2025 full-year result was $322000.0, down 11.29% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $32.4 million, up from $322000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $32.4 million in Q1 2022 and bottomed at $210000.0 in Q3 2024.
- The 5-year median for Other Non-Current Assets is $32.4 million (2022), against an average of $21.1 million.
- The widest annual swing landed in 2024, when Other Non-Current Assets slumped 99.35%; it then surged 15321.9% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $32.4 million in 2022, then changed by 0.0% to $32.4 million in 2023, then sank by 98.88% to $363000.0 in 2024, then dropped by 11.29% to $322000.0 in 2025, then soared by 9957.76% to $32.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $32.4 million (Q1 2026), $322000.0 (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 32.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.39 Mn |
| Dec 31, 2025 | 322,000.00 |
| Sep 30, 2025 | 32.39 Mn |
| Jun 30, 2025 | 346,000.00 |
| Mar 31, 2025 | 354,000.00 |
| Dec 31, 2024 | 363,000.00 |
| Sep 30, 2024 | 210,000.00 |
| Jun 30, 2024 | 32.39 Mn |
| Mar 31, 2024 | 32.39 Mn |
| Dec 31, 2023 | 32.39 Mn |
| Sep 30, 2023 | 32.39 Mn |
| Jun 30, 2023 | 224,000.00 |
| Mar 31, 2023 | 32.39 Mn |
| Dec 31, 2022 | 32.39 Mn |
| Sep 30, 2022 | 32.39 Mn |
| Jun 30, 2022 | 32.39 Mn |
| Mar 31, 2022 | 32.39 Mn |
| Dec 31, 2021 | 32.39 Mn |
| Sep 30, 2021 | 32.39 Mn |
| Jun 30, 2021 | 32.39 Mn |
| Mar 31, 2021 | 315,000.00 |
| Dec 31, 2020 | 32.39 Mn |
| Sep 30, 2020 | 449,000.00 |
| Jun 30, 2020 | 511,000.00 |
| Mar 31, 2020 | 572,000.00 |
| Dec 31, 2019 | 639,000.00 |
| Sep 30, 2019 | 688,000.00 |
| Jun 30, 2019 | 755,000.00 |
| Mar 31, 2019 | 805,000.00 |
| Dec 31, 2018 | 869,000.00 |
| Sep 30, 2018 | 934,000.00 |
| Sep 30, 2017 | 70,000.00 |
| Jun 30, 2017 | 15,000.00 |
| Mar 31, 2017 | 120,000.00 |
| Dec 31, 2016 | 15,000.00 |
| Sep 30, 2016 | 270,000.00 |
| Jun 30, 2016 | 270,000.00 |
| Mar 31, 2016 | 270,000.00 |
| Dec 31, 2015 | 45,000.00 |
| Sep 30, 2015 | 45,000.00 |
| Jun 30, 2015 | 270,000.00 |
| Mar 31, 2015 | 45,000.00 |
| Dec 31, 2014 | 200,000.00 |
| Sep 30, 2014 | 21,000.00 |
| Dec 31, 2013 | 50,000.00 |